Home  Media Press releases 2004
|
|
|
| 6 December 2004 | 2004-12-06T13:00:00.0000000-00:00 |
| ASTRAZENECA ANNOUNCES COMPLETION OF ENROLMENT IN SAINT I PHASE III TRIAL OF CEROVIVE® (NXY-059)
AstraZeneca announced today that it has ahead of schedule completed the enrolment of patients in SAINT I, one of two Phase III trials (SAINT I and II) being conducted to determine the effect of CEROVIVE (NXY-059) on disability and neurological recovery in acute ischaemic stroke patients. | Enrolment is continuing in the parallel Phase III trial (SAINT II) and in a Phase IIb trial (CHANT - Cerebral Haemorrhage And NXY-059 Treatment). SAINT I and II are two multinational, multi-centre, double-blind, randomized, placebo-controlled parallel-group studies designed to determine the effect of CEROVIVE (NXY-059) on disability and neurological recovery in acute ischaemic stroke patients. CHANT is a double-blind, randomized, placebo-controlled, parallel-group, multi-centre study to assess the safety and tolerability of 72 hours intravenous infusion of CEROVIVE (NXY-059) in adult patients with acute intracerebral haemorrhage.
The SAINT trials for CEROVIVE (NXY-059) are being conducted worldwide and are planned to enrol more than 3,000 subjects in approximately 400 centres across approximately 40 countries (Europe, Asia, Australia, New Zealand, South Africa, United States, Canada and Latin America) to evaluate the effect of the compound in acute ischaemic stroke patients. The safety of patients included in the trials is being continually evaluated. The CHANT trial will involve at least 150 centres in 21 countries.
CEROVIVE (NXY-059), a neuroprotectant with free-radical trapping properties, is a drug under development by AstraZeneca and licensed from Renovis, Inc.
For further information contact:
Media Enquiries:
Edel McCaffrey, Tel: +44 (0) 207 304 5034
Steve Brown, Tel: +44 (0) 207 304 5033
Investor Enquiries:
Mina Blair, Tel: +44 (0) 207 304 5084
Jonathan Hunt, Tel: +44 (0) 207 304 5087
Notes to Editors:
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products.
AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.
CEROVIVE™ (NXY-059) is a registered trademark of the AstraZeneca group of companies.
|
For business and financial media
|
|
|
|
|